Jeffrey Demoss, DO
Family Medicine · Tucson, AZNPI 1568487841
Payments from drug & device makers
Across 43 payments — averaging $16.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$213
- Novo Nordisk$77
- Boehringer Ingelheim$52
- Johnson & Johnson$48
- Pfizer$39
- Lilly USA, LLC$38
- plus $244 from 12 others
What the payments were for
- Food & beverage$70499%
- Education$61%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 11 | $213 |
| Novo Nordisk | 4 | $77 |
| Boehringer Ingelheim | 3 | $52 |
| Johnson & Johnson | 3 | $48 |
| Pfizer | 3 | $39 |
| Lilly USA, LLC | 3 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $32 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| Amgen | 2 | $29 |
| Merck | 2 | $23 |
| Astellas Pharma US Inc | 1 | $22 |
| Exact Sciences | 1 | $20 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| GSK | 1 | $14 |
| Shire North American Group Inc | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $12 |
How this compares
$710 in reported general payments places this provider in the 65th percentile of 2,099 family medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 176 | $231,837 |
| EliquisApixaban | 59 | $77,344 |
| TrulicityDulaglutide | 57 | $74,137 |
| OzempicSemaglutide | 41 | $57,614 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $45,041 |
| MounjaroTirzepatide | 37 | $44,932 |
| XareltoRivaroxaban | 19 | $28,853 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $13,726 |
| MyrbetriqMirabegron | 21 | $13,425 |
| EntrestoSacubitril/Valsartan | 12 | $11,148 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $10,332 |
| Arnuity ElliptaFluticasone Furoate | 15 | $5,769 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $3,870 |
| Atorvastatin Calcium | 458 | $3,385 |
| Levothyroxine Sodium | 340 | $2,848 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $52 | $231,837176 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $38 | $119,06994 claims |
| PfizerEliquis | $39 | $77,34459 claims |
| Novo NordiskOzempic | $77 | $57,61441 claims |
| GSKTrelegy Ellipta, Arnuity Ellipta | $14 | $50,81179 claims |
| Johnson & JohnsonXarelto | $48 | $28,85319 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $14 | $13,72615 claims |
| Astellas Pharma US IncMyrbetriq | $22 | $13,42521 claims |
| AstraZenecaSymbicort | $213 | $10,33233 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Tucson
- Dena PetersenTucson$14.7M
- John McGettiganTucson$8.3M
- Kevin PoundsTucson$1.9M
- Thili KulatilakeTucson$1.8M
- Judith BrownTucson$399K
- Hannah LeslieTucson$228K
- Charles MichieliTucson$111K
- Danielle ArmasScottsdale$73M
- Terry O'ReillyMesa$35.8M
- Shawn SearleChandler$27M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.